ProCE Banner Activity

LAPTOP: Integrase vs Protease Inhibitor–Based ART Regimens for Treatment-Naive People Living With Advanced HIV Disease

Conference Coverage
Slideset

Results of the LAPTOP trial suggest that, in treatment-naive people living with advanced HIV disease, an ART regimen containing bictegravir was noninferior to ART containing darunavir/cobicistat and was associated with lower rates of virologic failure and fewer overall adverse events.

Released: March 19, 2025

Expiration: September 18, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare